Lumosa Therapeutics Co., Ltd.
- Biotech or pharma, therapeutic R&D
Lumosa Therapeutics Co., Ltd. (TWO:6535) is a publicly traded, clinical-stage biopharmaceutical company headquartered in Taipei, Taiwan.
Our lead asset, LT3001, is a novel, first-in-class small molecule for the treatment of acute ischemic stroke (AIS). LT3001 has successfully completed 2 Phase II clinical trials across the U.S., EU, China, and Taiwan, demonstrating strong efficacy and a bleeding-free safety profile with an extended treatment window of up to 24 hours post-onset.
Lumosa is actively seeking global partners to support Phase 3 development and commercialization of LT3001, as well as co-development opportunities across the pipeline.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}